- Current report filing (8-K)
13 April 2010 - 3:38AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): April 12, 2010
BIO-BRIDGE
SCIENCE, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
000-51497
|
20-1802936
|
|
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
1211 West 22nd Street, Suite 615, Oak Brook,
Illinois
|
60523
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
630-928-0869
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
This
Form 8-K and other reports filed by the Registrant from time to time with the
Securities and Exchange Commission (collectively the “Filings”) contain forward
looking statements and information that are based upon beliefs of, and
information currently available to, the Registrant’s management as well as
estimates and assumptions made by the Registrant’s management. When used in the
Filings the words “anticipate”, “believe”, “estimate”, “expect”, “future”,
“intend”, “plan” or the negative of these terms and similar expressions as they
relate to the Registrant or the Registrant’s management identify forward looking
statements. Such statements reflect the current view of the Registrant with
respect to future events and are subject to risks, uncertainties, assumptions
and other factors relating to the Registrant’s industry, operations and results
of operations and any businesses that may be acquired by the Registrant. Should
one or more of these risks or uncertainties materialize, or should the
underlying assumptions prove incorrect, actual results may differ significantly
from those anticipated, believed, estimated, expected, intended or
planned.
Item
8.01 Other Events
On April 12, 2010, Bio-Bridge
Science, Inc. ("Bio-Bridge Science") issued a press release announcing that the
Company was granted a patent in Japan for the papilloma pseudovirus technology,
exclusively licensed from Loyola University Chicago. A copy of the press release
is attached hereto as Exhibit 99.1.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits
Exhibit Number
|
|
Description
|
|
|
|
99.1
|
|
Press
Release issued by Bio-Bridge Science, Inc., dated April 12,
2010
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
BIO-BRIDGE
SCIENCE, INC.
|
|
|
|
Date:
|
April
12, 2010
|
|
|
By:
|
|
/s/ Dr. Liang Qiao
|
Name
|
|
Dr.
Liang Qiao
|
Title:
|
|
Chief
Executive Officer
|
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024